Benzothiazole derivatives as human DNA topoisomerase IIα inhibitors

被引:0
|
作者
Cigdem Kaplan-Ozen
Betul Tekiner-Gulbas
Egemen Foto
Ilkay Yildiz
Nuran Diril
Esin Aki
Ismail Yalcin
机构
[1] Hacettepe University,Biology Department, Molecular Biology Section, Faculty of Science
[2] Bilkent University,BilGen Genetics and Biotechnology Center, Department of Molecular Biology and Genetics
[3] Ankara University,Pharmaceutical Chemistry Department, Faculty of Pharmacy
来源
Medicinal Chemistry Research | 2013年 / 22卷
关键词
Benzothiazole derivatives; Human topoisomerase IIα; DNA binding; Intercalation; Catalytic inhibitor; Anticancer drugs;
D O I
暂无
中图分类号
学科分类号
摘要
Benzothiazole derivatives resembling the structure of DNA purine bases were tested to determine their topoisomerase inhibition activities. Based on DNA topoisomerase I and II relaxation assay results, all 12 derivatives acted as human topoisomerase IIα inhibitors, whereas only two compounds inhibited Calf thymus topoisomerase I. 3-amino-2-(2-bromobenzyl)-1,3-benzothiazol-3-ium 4-methylbenzensulfonate (BM3) was observed to be the most effective human topoisomerase IIα inhibitor with the lowest IC50 value of 39 nM. The mechanistic studies suggested that BM3 was neither a DNA intercalator nor a topoisomerase poison, it was only a DNA minor groove-binding agent. BM3 initially bound to the DNA topoisomerase IIα enzyme, then to DNA. As a result, the tested benzothiazole derivatives were obtained as strong topoisomerase IIα inhibitors. The benzothiazole tosylated salt form BM3 was found as the most effective topoisomerase IIα inhibitor. BM3’s mechanisms of action might be its direct interaction with the enzyme. BM3’s minor groove-binding property might also contribute to this action. Hence, BM3 could be a good candidate as a new anticancer agent.
引用
收藏
页码:5798 / 5808
页数:10
相关论文
共 50 条
  • [1] Benzothiazole derivatives as human DNA topoisomerase IIα inhibitors
    Kaplan-Ozen, Cigdem
    Tekiner-Gulbas, Betul
    Foto, Egemen
    Yildiz, Ilkay
    Diril, Nuran
    Aki, Esin
    Yalcin, Ismail
    MEDICINAL CHEMISTRY RESEARCH, 2013, 22 (12) : 5798 - 5808
  • [2] Discovery of novel triazolophthalazine derivatives as DNA intercalators and topoisomerase II inhibitors
    Sakr, Helmy
    Ayyad, Rezk R.
    El-Helby, Ali A.
    Khalifa, Mohamed M.
    Mahdy, Hazem A.
    ARCHIV DER PHARMAZIE, 2021, 354 (06)
  • [3] NOVEL LIGNAN DERIVATIVES AS SELECTIVE INHIBITORS OF DNA TOPOISOMERASE-II
    KASHIWADA, Y
    BASTOW, KF
    LEE, KH
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1995, 5 (08) : 905 - 908
  • [4] Catalytic inhibitors of DNA topoisomerase II
    Andoh, T
    Ishida, R
    BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1998, 1400 (1-3): : 155 - 171
  • [5] Mannich Base Derivatives as the Potential Candidates of Human Topoisomerase II Inhibitors
    Istanbullu, Huseyin
    Senarisoy, Muge
    Erciyas, Ercin
    Topcu, Zeki
    LETTERS IN DRUG DESIGN & DISCOVERY, 2015, 12 (02) : 103 - 108
  • [6] Design and in silico Prediction of New Methylenedioxyphenyl Derivatives as DNA Topoisomerase II Inhibitors
    Rathore, Swati
    Reddemma, Maadhu
    Rai, Neha
    Tiwari, Richa Tripathy
    Begum, Shaheen
    Patil, Shailendra
    Patil, Asmita Gajbhiye
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL INVESTIGATION, 2023, 13 (03) : 548 - 558
  • [7] DNA topoisomerase I, DNA topoisomerase IIα, and DNA topoisomerase IIβ as markers for human tumors.
    Foglesong, PD
    Reyes, A
    Breitenstein, H
    Martin, L
    D'Andrea, MR
    Connolly, RT
    Szcykalski, LM
    FASEB JOURNAL, 1998, 12 (04): : A197 - A197
  • [8] Bioassays and In Silico Methods in the Identification of Human DNA Topoisomerase IIα Inhibitors
    Bergant, Kaja
    Janezic, Matej
    Perdih, Andrej
    CURRENT MEDICINAL CHEMISTRY, 2018, 25 (28) : 3286 - 3318
  • [9] Acridine derivatives as inhibitors/poisons of topoisomerase II
    Kozurkova, Maria
    JOURNAL OF APPLIED TOXICOLOGY, 2022, 42 (04) : 544 - 552
  • [10] Xanthocidin Derivatives as Topoisomerase IIα Enzymatic Inhibitors
    Takeda, Shuso
    Yaji, Kentaro
    Matsumoto, Kenji
    Amamoto, Toshiaki
    Shindo, Mitsuru
    Aramaki, Hironori
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2014, 37 (02) : 331 - 334